Development and adaptation of patient-reported outcome measures for patients who experience itch associated with primary biliary cholangitis by Martin ML et al.
   Journal of Patient-
Reported Outcomes
Martin et al. Journal of Patient-Reported Outcomes             (2019) 3:2 
https://doi.org/10.1186/s41687-018-0090-1RESEARCH Open AccessDevelopment and adaptation of patient-
reported outcome measures for patients
who experience itch associated with
primary biliary cholangitis
Mona L. Martin1*, Larissa Stassek1, Steven I. Blum2 , Ashish V. Joshi2 and David Jones3Abstract
Purpose: To conduct qualitative interviews to evaluate and refine the Itch Diary (ID) and weekly version of the
PBC-40 in patients with itching associated with primary biliary cholangitis (PBC).
Methods: Twenty adults with self-reported PBC diagnoses and recent/ongoing itching of at least moderate intensity
participated in face-to-face qualitative combined concept elicitation (CE) interviews and cognitive interviews after
completing the morning and evening versions of the ID and weekly version of the PBC-40. These questionnaires were
evaluated to confirm saturation of concepts of interest and cognitively test the English language versions of the
measures in patients with PBC in the US and Canada. Transcripts were organized into descriptions of PBC-related
symptoms and symptom-related impacts using a structured coding framework. Two waves of interviews were
conducted; revisions made after wave 1 were further tested in wave 2.
Results: Interview results confirmed the relevance of concepts presented in the PBC-40 and ID to patients’ experiences.
Saturation of concept was achieved. Itching-related signs and symptoms (46%) were the most commonly expressed
symptom concept in the CE interviews followed by energy-related (14%) and additional signs/symptoms (13%). Several
changes to the ID were made in response to cognitive interview results. Changes to the PBC-40 included adaptations
from British to North American English, and the appropriateness of a 7-day recall period was confirmed.
Conclusions: Relevance of the symptom and impact concepts in the ID to measure PBC-related itch were confirmed.
Adaptation of the PBC-40 to a weekly recall period and for North American English was successful.
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Primary biliary cholangitis (PBC), previously known as
primary biliary cirrhosis, is a chronic autoimmune disease
of the liver in which intrahepatic small bile ducts are
selectively destroyed by inflammatory cells [1, 2]. The dis-
ease is progressive and eventually results in liver fibrosis
[2]. PBC is relatively uncommon, with a prevalence of up
to 39.2 per 100,000 in the United States [3], and has a
strong predominance in women [3, 4].* Correspondence: martin@hrainc.net
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the Creative Commons license, and indicate ifItching (pruritus) is an extrahepatic symptom of PBC
that occurs in an estimated 55% of patients [5]. The itch
may be severe and can have a significant impact on
patients’ health-related quality of life [6]. In a survey of 238
patients with PBC, the itching sensation was described as
“bugs crawling” or “relentless” and 3.6% reported they
scratched until they bled [7]. Nearly three-quarters of
patients reported that the itch interfered with sleep [7].
Scratching brings little to no relief and intense scratching
may cause serious damage to the skin [8]. The bile acid
sequestrant, cholestyramine is the only US Food and
Drug Administration (FDA)-approved treatment for PBC-
related itch, but it has an unpleasant taste and can cause
gastrointestinal side effects, limiting its clinical uptake.is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
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many other common medications (e.g., warfarin, digoxin,
seizure medications, levothyroxine, antibiotics, etc) [1, 8].
Itch is a sensation that cannot be directly observed, and
is only known to the individual, making its assessment
subjective and difficult to quantify [8]. Patient-reported
outcome (PRO) measures for PBC-related itch are limited.
Tools used to date include a simple grading of worst itch
over a certain period (e.g., the past 7 days) on a numeric
rating scale (e.g., 0 to 10) or on a Visual Analogue Scale
(VAS) and the 5-D itch scale [8]. The 5-D itch scale is a
brief and easy-to-complete measure designed to specific-
ally evaluate the extent and impact of itch across a range
of conditions, but it was not developed using qualitative
interviews with PBC patients [9]. On the other hand, the
PBC-40 is a PBC-specific, health-related quality-of-life
questionnaire, but it only has 3 questions to assess itch
and these questions may not be sufficient to cover the
spectrum of itching, which is a key symptom in this target
population [10]. Additionally, the original version of the
PBC-40 has a 4-week recall period, which may not be ideal
for measuring daily variability in patient’s itch experience.
The Patient Reported Symptoms Questionnaire (“Itch
Diary”) was developed to meet the need for a PBC-
specific itch PRO measure and was based on key con-
cepts in the PBC-40 [11, 12]. The questionnaire focuses
on itch, but also contains items for a few other PBC
symptoms such as fatigue and diarrhea. Initial cognitive
testing was conducted through interviews with 10 partici-
pants with PBC, and the Itch Diary was preliminarily used
in a phase 2a safety and tolerability study of GSK2330672,
an ileal bile acid transporter inhibitor under development
for PBC-related itch [13]. In order to ensure greater accur-
acy in the recall of symptoms, the phase 2a study also pre-
liminarily evaluated the PBC-40 during a 2-week placebo
run-in period using a “past 2 weeks” recall period, in con-
trast to the original recall period of “last 4 weeks” [10, 14].
However, it was still unclear as to whether the list of
symptoms was complete in terms of key concepts relevant
to those with PBC.
An integral part of developing quality-of-life measures
is to conduct qualitative patient interviews and such in-
terviews are recommended by the FDA for the develop-
ment of PRO measures [15, 16]. The objective of the
current study was to further develop and cognitively test
English versions of the Itch Diary and the weekly version
of the PBC-40 in North American individuals with PBC
and related itching, and to identify any other potential
concepts that might be relevant to patients’ experiences.
Methods
Study design and participants
While the qualitative sample of ten patients in the previ-
ous study at times may be acceptable for rare conditions,it was still unclear whether the list of symptoms identi-
fied in the earlier study was complete in terms of the key
concepts relevant to people with PBC, and whether the
content was transferrable to other countries and cultures.
Therefore, we conducted additional qualitative interviews
in patients with PBC to confirm saturation of the concepts
of interest and the applicability of these concepts within
the US and Canada. In-person qualitative interviews
consisting of concept elicitation (CE) and cognitive por-
tions were conducted in the US and Canada to collect
data for confirming content relevance, instrument feasi-
bility, and saturation of concept for the Itch Diary and
the weekly version of the PBC-40. Interviews lasted for
about 90 min, beginning with the CE portion of the
interview, then completion of questionnaires of interest
(PBC-40, Itch Diary) as well as some additional secondary
questionnaires (Weekly Gastrointestinal Diary; Patient
Global Impression of Severity for Itch [PGIS-Itch] and
Patient Global Impression of Change for Itch [PGIC-Itch];
and 5-D itch scale), followed by the cognitive portion of
the interview.
Men and women aged 18 to 80 years who self-reported
a diagnosis of PBC were recruited via local and national
patient groups. Participants were required to have ongoing
itching of at least moderate intensity (equivalent to a score
of ≥4 on the numerical response scale [NRS; range 0–10])
during the previous 8 weeks. Individuals with a self-
reported history of liver disease of other etiology or
reporting other highly symptomatic medical conditions
(i.e., inflammatory bowel disease, chronic plaque psoriasis,
eczema, etc) were excluded. As PBC predominantly affects
women [3, 4], a majority of the sample was expected to be
female.
Study recruitment was conducted via advertisements
to members of patient groups in the US and Canada:
PBCers and the Canadian PBC Society. The study was
conducted in compliance with Health Insurance Portability
and Accountability Act regulations, and all participants
provided written informed consent. The study was
approved by an Institutional Review Board (Quorum
Review IRB, Seattle, WA, USA).Data collection
Demographic and basic comorbidity data were collected
from each participant. Those who were willing, signed a
Medical Information Release Waiver giving their consent
for additional limited medical information to be obtained
from their medical provider. Information collected from
the medical provider, when authorized, included date of
PBC diagnosis, current and past medications for itching/
pruritus, previous history of liver transplant (yes/no),
and, when possible, the most recent bilirubin and alkaline
phosphatase lab results.
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Interviewers were experienced in interviewing techniques
for PRO measurement development and in conducting
one-on-one interviews across a wide range of therapeutic
areas. Training for the interviewers included an instruc-
tion session specific to the study, review of the interview
guide, and observed practice interviews.
Interviews were conducted in 2 waves of 10 participants
each. Revisions to the PRO measures were made in re-
sponse to participant input from the first wave, and then
tested in the second wave. During the CE portion of the
interviews, participants were asked open-ended questions
in order to elicit spontaneous reports of the patient’s
experience, followed by probing questions designed to
more fully explore participant experiences with PBC
symptoms (including frequency, severity, and variation
of symptoms) and the impact of PBC on emotions,
daily activities, social functioning, sleep, etc. During the
cognitive portion of the interviews, participants were
asked a series of structured and semi-structured questions
designed to obtain feedback on the PRO measures. Topics
covered were the participants’ interpretation of the indi-
vidual items, how they regarded the fit and adequacy of
the response scales and recall periods, and how comfort-
able they were with the terminology used. Participants
were also asked to discuss the relevance of PRO items and
whether any other important concepts were missing and
should be considered for addition.
PRO measures of interest were administered to each
participant on paper between the CE and cognitive portions
of the interview. The PROs of main interest were the Itch
Diary (AM and PM versions) and a weekly version of the
PBC-40 that used a 7-day recall period as opposed to the
original 4-week recall period [10]. The PBC-40 contains 40
questions covering 6 domains (symptoms, itch, fatigue, cog-
nition, social, and emotional), and 3 additional questions
measuring general health status [10]. The PGIS-Itch and
PGIC-Itch were also evaluated to confirm their rele-
vance as suitable anchor measures for use in future
studies to assess the psychometric properties of the Itch
Diary and the weekly version of the PBC-40.
Data analysis
Transcripts from the CE portion of the interview were
organized into descriptions of PBC-related symptoms and
symptom impacts by developing a coding framework and
coding dictionary. Two coders were used during the study.
Inter-rater agreement was evaluated by independent dual
coding of 2 of the 20 transcripts and comparing the
coding differences and expressing coding consistency
by percentage of agreement in the codes assigned.
A saturation table was used to track symptoms and
impacts from the concept elicitation portion of the inter-
views. The transcripts were ordered chronologically, basedon interview completion date, and then grouped into four
groups of five transcripts each. Concept saturation was then
evaluated by comparing the codes in each new transcript
group with the codes in the previous group to identify
newly appearing information. When new codes no longer
appeared, no new information was being obtained; this is
called “saturation of concept” meaning no further informa-
tion is likely to be gained by continuing interviews in the
same population.
Descriptive statistics were generated for demographic
and concept rating data. Information for the cognitive
portion of the interviews was collected into a summary
grid that organized and related the response from each
participant to the item that was queried. Difficulties in
understanding the item content were also noted in the
cognitive summary grid.
Results
Population characteristics
Of the 20 participants interviewed in the study, the
mean age was 57.4 years and 90% were women (Table 1).
Most (90%) participants were white and 10% were Hispanic.
Fourteen were in the US (Seattle, WA; Austin, TX; El Paso,
TX; Lansing, MI; Grand Rapids, MI; New York City, NY;
and San Francisco, CA) and 6 were in Canada (Toronto,
ON; Victoria, BC; and Vancouver, BC). The majority (55%)
were employed full-time, whereas 30% were retired. The
most common comorbidities were allergies (50%) and
arthritis (50%), and the mean severity of worst itch
based on a 101-point NRS was 89.3 (a score of 100
represents the “Worst Itching You Can Imagine” and 0
represents “NO Itching at All”).
Sixteen patients signed the optional Medical Information
Release Form authorizing the study team to request limited
medical information from their medical provider. Of the
16 forms sent to providers, 10 were returned. Four add-
itional patients brought their own medical records to the
interviews. Therefore, additional limited medical informa-
tion from medical providers was available for 14 partici-
pants. PBC diagnosis was confirmed in all 14 patients, with
a mean (standard deviation) duration of disease of 9.6 (6.0)
years. Twelve of these 14 participants (86%) had received
ursodeoxycholic acid (past or present) to treat their PBC.
Only 4 reported they were currently using medication to
relieve their itching.
Patients who were screened but did not fully meet the
eligibility criteria were considered on an individual basis
to determine whether the particular criteria deviation
might lead to confounding or conflict with the study design
or objectives. Four of these subjects were authorized to
participate despite not meeting one or more eligibility
criteria, one subject cancelled the interview and the
three remaining subjects were interviewed and included
in the analysis. Of those included, 1 patient reported
Table 1 Participant demographic and disease characteristics
Characteristic N = 20
Age, y
Mean (SD) 57.4 (11.2)
Range 32–74
Female, n (%) 18 (90)
Race, n (%)
White 18 (90)
Hispanic 2 (10)
Highest level of education completed, n (%)
High school 1 (5)
Some college 7 (35)
Bachelor’s degree 6 (30)
Graduate or professional school 6 (30)
Current employment status, n (%)
Full time 11 (55)
Part time 1 (5)
Unemployed for > 1 year 1 (5)
Retired 6 (30)
Unable to work because of PBC, CPS/fibromyalgia 1 (5)
Household income, US $, n (%)
$15,000–$24,999 2 (10)
$25,000–$34,999 1 (5)
$35,000–$49,999 2 (10)
$50,000–$74,999 6 (30)
$75,000–$99,999 2 (10)
$100,000–$124,999 1 (5)
≥$125,000 5 (25)
Declined to answer 1 (5)
Comorbidities, n (%)a
Allergies (hay fever, chronic sinus trouble, other) 10 (50)
Arthritis or rheumatism 10 (50)
Asthma or other severe lung problemsb 4 (20)
Back problems (including disc or spine) 7 (35)
Depression 2 (10)
Diabetes or high blood sugar 3 (15)
Headache or migraine 3 (15)
Heart troublec 1 (5)
High blood pressure or hypertension 7 (35)
Nervousness or anxiety disorder 2 (10)
Thyroid problems 1 (5)
Trouble seeing (even with glasses or contact lenses) 4 (20)
Itch NRS (scale 0–100)d
Severity of worst itch, mean (SD) 89.3 (14.1)
Severity of usual amount of itch, mean (SD) 50.5 (24.5)
CPS, chronic pain syndromes; NRS numerical response scale; PBC primary biliary
cholangitis; SD, standard deviation; US, United States
aOne participant each (5%) reported celiac disease, chronic reflux, fibromyalgia,
hepatitis C, mixed nonspecific autoimmune disease, osteoarthritis, osteoporosis,
polyps, Raynaud’s disease, Sjogren’s syndrome, or sphincter of Oddi dysfunction
bChronic bronchitis, chronic obstructive pulmonary disorder, or emphysema
cAngina, congestive heart failure, coronary artery disease, use of cardiac pacemaker
dDuring the concept elicitation portion of the interview, participants were asked to
complete a series of rating exercises using a NRS, with the 0 end of the scale
representing “NO Itching at All,” and 100 representing “Worst Itching You Can Imagine”
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although this patient reported having itching above a 4 at
times during the recall period; 1 patient had been diag-
nosed with hepatitis C, but had been declared cured after
treatment for the infection; and 1 patient reported infre-
quent minor flare-ups of eczema but was not experiencing
eczema during screening or the interview for the current
study.
Concept elicitation (CE) interviews
Saturation of concept (the point where no new concepts
emerged) for the Itch Diary was reached by the end of the
third transcript group (i.e., 4 groups with 5 transcripts
each). Inter-rater agreement in assignment of codes be-
tween the 2 raters was high at 94% and 95% for the 2
dual-coded transcripts.
The CE portion of the interviews confirmed relevance
of the concepts presented in the items of the PBC-40
and Itch Diary (both AM and PM versions). Itching-
related signs and symptoms were reported by all patients,
and was the most commonly expressed symptom subdo-
main when assessed by symptom concept code frequency
(46% of all symptom expressions) followed by energy-related
concepts (14% of total symptoms expressed) and additional
signs and symptoms (13% of total symptoms expressed)
(Table 2). Specific codes in terms of how patients described
the term and additional descriptors are reported in Table 2.
During the CE portion of the interview, participants
were given the opportunity to spontaneously report
symptoms related to their PBC before follow-up probing
questions were asked. The symptom concepts most
often mentioned spontaneously were “fatigue” (75%; 15/
20 participants) and “itching on the legs” (75%; 15/20
participants). Other common spontaneously reported
symptom concepts were “itching on the arms” (55%; 11/20
participants), “itching on the side” (45%; 9/20 participants),
and “itching on the back” (45%; 9/20 participants). Follow-
up probing questions did not notably increase the reports
related to itching, although the number of participants
reporting weakness, gastrointestinal signs and symptoms,
cognitive signs and symptoms, and pain and discomfort
were markedly increased (Table 3).
During the interview, participants were asked to refer
to the symptoms they had described and identify the top
1 or 2 symptoms that were the worst for them. The
symptoms most commonly chosen were itching (worst
in 40% of participants, second worst in 25% of partici-
pants) and fatigue (worst in 35% of participants, second
worst in 35% of participants). Participants identified the
most common location for itching as legs (75%), followed
by arms (65%), torso (60%), and feet (50%).
A series of questions was asked during the CE portion of
the interviews to explore the impact of PBC on patients’
lives and the language used by participants to describe these
Table 2 Summary of symptom concept code frequency totals
by subdomain
PBC Symptom
Subdomains and
Concepts
Total Language
Expressions Within
Concept, n (%)
N = 642
Transcripts Contributing
to Concept Expressions,
n (%)
N = 20
Itching-related signs and
symptoms
293 (46) 20 (100)
Itching 254 (39.6) 20 (100)
Hives 12 (1.9) 3 (15)
Burning 9 (1.4) 3 (15)
Rash 9 (1.4) 3 (15)
Tingling 8 (1.2) 4 (20)
Dry patches 1 (0.2) 1 (5)
Energy-related signs and
symptoms
87 (14) 18 (90)
Fatigue 44 (6.9) 17 (85)
Tiredness 16 (2.5) 9 (45)
Low energy 14 (2.2) 6 (30)
Exhaustion 8 (1.2) 7 (35)
Weakness 5 (0.8) 4 (20)
Additional signs and
symptoms
86 (13) 19 (95)
Other symptomsa 20 (3.1) 11 (55)
Dry eyes 13 (2.0) 10 (50)
Gallstones 9 (1.4) 8 (40)
Dry mouth 8 (1.2) 8 (40)
Weak/brittle bones 8 (1.2) 5 (25)
Fat deposits on skin 8 (1.2) 6 (30)
Darkening of skin 8 (1.2) 6 (30)
Hair loss 3 (0.5) 2 (10)
Jaundice 3 (0.5) 2 (10)
Sleep disturbance 3 (0.5) 3 (15)
Swelling 3 (0.5) 3 (15)
Pain and discomfort 77 (12) 19 (95)
Joint pain/aches 23 (3.6) 10 (50)
Discomfort in right side 21 (3.3) 11 (55)
Muscle pain/aches 9 (1.4) 5 (25)
General pain 8 (1.2) 6 (30)
Other pain and
discomfort
8 (1.2) 8 (40)
Abdominal pain 4 (0.6) 4 (20)
Bone pain/aches 4 (0.6) 3 (15)
GI signs and symptoms 69 (11) 16 (80)
Diarrhea 17 (2.6) 10 (50)
Nausea 12 (1.9) 7 (35)
Abdominal bloating 11 (1.7) 10 (50)
Other GI symptoms 10 (1.6) 7 (35)
Table 2 Summary of symptom concept code frequency totals
by subdomain (Continued)
PBC Symptom
Subdomains and
Concepts
Total Language
Expressions Within
Concept, n (%)
N = 642
Transcripts Contributing
to Concept Expressions,
n (%)
N = 20
Urgency with bowel
movements
7 (1.1) 7 (35)
Greasy diarrhea 6 (0.9) 5 (25)
Indigestion/heartburn 3 (0.5) 3 (15)
Changes in appetite 3 (0.5) 3 (15)
Cognitive signs and
symptoms
30 (5) 10 (50)
Difficulty concentrating 11 (1.7) 7 (35)
Difficulty remembering
things
9 (1.4) 7 (35)
Other cognitive
symptoms
4 (0.6) 2 (10)
Brain fog 3 (0.5) 2 (10)
Confusion 3 (0.5) 2 (10)
GI, gastrointestinal; PBC, primary biliary cholangitis
aOther symptoms include: bruises easily, cellulitis, changes in taste, chest
infections, eye problems, fibromatosis, flushed, fluid in abdomen, heat
intolerance, kidney stones, no hair growth, redness, restless legs, shingles,
shortness of breath, and sweating
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monly expressed impact subdomain when assessed by im-
pact concept code frequency (21% of total impact
expressions) followed by emotional functioning (18% of total
impact expressions) and sleep difficulties (17% of total im-
pact expressions) (Table 4).
Within these subdomains, the most frequently cited con-
cepts overall were “scratching until skin is raw/infected” (38
expressions by 16 participants [80%]) in the additional im-
pacts subdomain, “difficulty staying asleep” (38 expressions
by 16 participants [60%]) in the sleep difficulties subdomain,
“social activities limited” (37 expressions by 14 participants
[70%]) in the limitations to relationships and social function-
ing subdomain, “limitations at work” (34 expressions by 15
participants [75%]) in the changes to daily performance sub-
domain, and “needing to change their diet” (32 expressions
by 15 participants [75%]) in the limitations to lifestyle and
activities subdomain.
Similar to the symptom concepts, participants were
allowed to spontaneously report impact concepts related to
their PBC before follow-up probing questions were asked.
The impact concepts most often mentioned spontaneously
were “limitations at work” (65%; 13/20 participants) and
“difficulty staying asleep” (65%; 13/20 participants). Other
common spontaneously reported impact concepts were
“needing to change their diet” (60%; 12/20 participants) and
“scratching until skin is raw/infected” (55%; 11/20 par-
ticipants). Follow-up probing questions increased the
Table 3 Spontaneous vs probed symptom expressions during the CE portion of the interviews
Symptom Reported, n (%) Participants, N = 20
Spontaneous Probed Not Affected Not Reported
Itching-related signs and symptoms
Itching on the legs 15 (75) – – 5 (25)
Itching on the arms 11 (55) 2 (10) – 7 (35)
Itching on the back 9 (45) 1 (5) – 10 (50)
Itching on the sides 9 (45) 1 (5) – 10 (50)
Itching on the abdomen 7 (35) 2 (10) – 11 (55)
Itching on the head 6 (30) – – 14 (70)
Itching on the feet 3 (15) – – 17 (85)
Itching on the hands 3 (15) – – 17 (85)
Itching on the face 2 (10) 1 (5) – 17 (85)
Itching on the chest 1 (5) – – 19 (95)
Itching on the groin 1 (5) – – 19 (95)
Hives 1 (5) – – 19 (95)
Rash 1 (5) – – 19 (95)
Energy-related signs and symptoms
Fatigue 15 (75) 1 (5) 2 (10) 2 (10)
Tiredness 6 (30) – – 14 (70)
Lack of energy 3 (15) – – 17 (85)
Exhausted 2 (10) – – 18 (90)
Weakness 2 (10) 10 (50) 8 (40) –
Gastrointestinal signs and symptoms
Nausea 6 (30) – – 14 (70)
Diarrhea 4 (20) 8 (40) 8 (40) –
Othera 3 (15) 1 (5) – 16 (80)
Abdominal bloating 2 (10) 10 (50) 6 (30) 2 (10)
Changes in appetite – 5 (25) 14 (70) 1 (5)
Greasy diarrhea 1 (5) 7 (35) 11 (55) 1 (5)
Urgency with bowel movements – 12 (60) 7 (35) 1 (5)
Cognitive signs and symptoms
Difficulty concentrating 3 (15) 11 (55) 6 (30) –
Difficulty remembering things 2 (10) 12 (60) 6 (30) –
Pain and discomfort
Bone pain/aches 5 (25) 2 (10) – 13 (65)
Muscle pain/aches 4 (20) – – 16 (80)
Abdominal pain 3 (15) 9 (45) 7 (35) 1 (5)
Discomfort in right side 3 (15) 11 (55) 5 (25) 1 (5)
General pain – 4 (20) 4 (20) 12 (60)
Joint pain/aches 3 (15) 2 (10) – 15 (75)
Otherb 1 (5) 1 (5) – 18 (90)
Additional signs and symptoms
Dry eyes 6 (30) 8 (40) 6 (30) –
Difficulty staying asleep 5 (25) 11 (55) 4 (20) –
Dry mouth 4 (20) 9 (45) 7 (35) –
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Table 3 Spontaneous vs probed symptom expressions during the CE portion of the interviews (Continued)
Symptom Reported, n (%) Participants, N = 20
Spontaneous Probed Not Affected Not Reported
Hair loss 4 (20) – – 16 (80)
Otherc 4 (20) – – 16 (80)
Difficulty falling asleep 2 (10) 8 (40) 9 (45) 1 (5)
Weak/brittle bones 2 (10) 1 (5) 17 (85) –
Darkening of the skin 1 (5) 7 (35) 12 (60) –
Fatty deposits on skin 1 (5) 5 (25) 14 (70) –
Gall stones – 3 (15) 3 (15) 14 (70)
Jaundice 1 (5) 1 (5) 18 (90) –
Kidney stones – 5 (25) 9 (45) 6 (30)
Swelling – 10 (50) 10 (50) –
CE, concept elicitation
aAcid reflux, constipation, fewer stools, don’t process vitamins/minerals properly
bHeadache, migraine
cWeight gain, weight loss, restless legs, sweating, skin flushed, heavy menstruation
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cepts (Table 5).
Participants were also asked to choose 1 to 2 impacts that
were the worst for them. Responses varied widely, but 3
participants (15%) selected “general function/daily routine”
and 2 participants (10%) selected “reduced sleep quality.”
Cognitive interviews and PRO revisions
The cognitive portion of the interviews resulted in several
changes to the Itch Diary and PBC-40 (Table 6). During
wave 1, 2 items were dropped from the Itch Diary (1 from
the AM and 1 from the PM diary) because participants
felt that these were very similar to other items. The ques-
tion stems were changed in 6 items (1 in the AM and 5 in
the PM diary) to make the items clearer and easier to
answer. The response scale was changed from an NRS
version to a verbal response scale (VRS) version in 1 item
in the AM Itch Diary and 7 items in the PM Itch Diary
to reduce confusion in interpretation of answers. For
example, many of the questions asked “how much
time…” and some participants interpreted the numberTable 4 Summary of impact concept code frequency totals by subd
PBC Impact Subdomains and Concepts Total
Expre
N = 5
Changes in daily performance 119 (
Emotional functioning 103 (
Sleep difficulties caused by itching or other symptoms 98 (1
Limitations to relationships and social functioning 87 (1
Limitations to lifestyle and activities 84 (1
Additional impactsa 80 (1
PBC, primary biliary cholangitis
aDecreased quality of life, economic burden, scratching until skin is raw or infectedoptions as percentages, whereas others interpreted the
options as number of hours. Changing the response to
a VRS helped to more clearly and consistently define
each of the response options (i.e., “none of the time,” “a
little of the time,” etc).
Further revisions were made to question stems and
the response scale after wave 2. These changes included
additional wording changes to 1 of the items in the AM
and PM diaries, as well as changes to the response options
of these diaries; additionally, the NRS versions of select
items were added back into the measure for use in an up-
coming clinical trial for testing against the VRS versions.
Three of the item revisions in the PBC-40 during wave
1 were to adapt from British English in the original version
to terms more common in North America (i.e., “holiday”
vs “vacation”). During wave 2, additional revisions were
made to 3 items to further clarify their meaning. For
example, 1 item asked about aching in the long bones of
the patient’s arms and legs. Some participants had trouble
responding because they experienced aching in the
arms, but not in the legs or vice versa. Therefore, theomain
Participant Symptom
ssions Within Concept, n (%)
71
Transcripts Contributing to
Concept Expressions, n (%)
N = 20
21) 18 (90)
18) 19 (95)
7) 18 (90)
5) 16 (80)
5) 20 (100)
4) 19 (95)
, treatment burden, physical discomfort, and weight gain
Table 5 Spontaneous vs probed impact expressions during the CE portion of the interviews
Symptom Reported, n (%) Participants, N = 20
Spontaneous Probed Not Affected Not Reported
Emotional functioning
Anxiety 7 (35) 2 (10) 3 (15) 8 (40)
Embarrassment 5 (25) 1 (5) 3 (15) 11 (55)
Depression 4 (20) 1 (5) 3 (15) 12 (60)
Worry 3 (15) 5 (25) 3 (15) 9 (45)
Anger 2 (10) 2 (10) 3 (15) 13 (65)
Frustration 2 (10) 5 (25) 3 (15) 10 (50)
Stress 2 (10) 4 (20) 3 (15) 11 (55)
Guilt 1 (5) 3 (15) 3 (15) 13 (65)
Othera 1 (5) – – 19 (95)
Changes in daily performance
Work 13 (65) 2 (10) 3 (15) 2 (10)
General functioning/daily routine 4 (20) 5 (25) 3 (15) 8 (40)
Housework/chores 4 (20) 5 (25) 3 (15) 8 (40)
Needs to pace self 3 (15) 11 (55) 6 (30) –
Takes longer than usual to recover 3 (15) 14 (70) 2 (10) 1 (5)
Takes longer than usual to complete tasks 2 (10) 13 (65) 5 (25) –
Need to force self 1 (5) 12 (60) 7 (35) –
Otherb 1 (5) – 3 (15) 16 (80)
Limitations to lifestyle and activities
Changes to diet 12 (60) 3 (15) 4 (20) 1 (5)
Changes to alcohol consumption 7 (35) 6 (30) 6 (30) 1 (5)
Exercise/sports 5 (25) 5 (25) 6 (30) 4 (20)
Travel 5 (25) 2 (10) 6 (30) 7 (35)
Unable to plan things in advance 4 (20) 6 (30) 9 (45) 1 (5)
Clothing restrictions 2 (10) – – 18 (90)
Otherc – 1 (5) – 19 (95)
Limitations to social functioning
Social activities limited 8 (40) 6 (30) 6 (30) –
Family relations affected 6 (30) 4 (20) 9 (45) 1 (5)
Friends relations affected 5 (25) 2 (10) 8 (40) 5 (25)
Relationships with partner affected 3 (15) 3 (15) 8 (40) 6 (30)
Workplace relations affected 2 (10) 2 (10) 8 (40) 8 (40)
Otherd 1 (5) – – 19 (95)
Less interest in sex – 5 (25) 14 (70) 1 (5)
Sexual function issues – 3 (15) 14 (70) 3 (15)
Sleep difficulties caused by itching or other symptoms
Difficulty staying asleep 13 (65) 3 (15) 4 (20) –
Difficulty falling asleep 7 (35) – 4 (20) 9 (45)
Needs to take naps 3 (15) 7 (35) 10 (50) –
Reduced sleep quality 3 (15) 1 (5) 4 (20) 12 (60)
Wakes up too early 3 (15) 2 (10) 4 (20) 11 (55)
Goes to bed early – 10 (50) 10 (50) –
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Table 5 Spontaneous vs probed impact expressions during the CE portion of the interviews (Continued)
Symptom Reported, n (%) Participants, N = 20
Spontaneous Probed Not Affected Not Reported
Additional impacts
Scratching until skin is raw/infected 11 (55) 7 (35) 2 (10) –
Decreased quality of life 3 (15) 12 (60) 5 (25) –
Economic burden 2 (10) 6 (30) 11 (55) 1 (5)
Treatment burden 2 (10) 1 (5) – 17 (85)
CE, concept elicitation
aConcern about having children
bSchool
cGardening
dSocial stigma
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that participants could respond if they had aching in
only one location.
There were no major issues or revisions made to the
PGIS-Itch, PGIC-Itch, or 5-D Itch measures; the PGIS-
Itch and PGIC-Itch were determined to be appropriate
anchor measures.
During wave 1, the response options were revised for
1 item (“always” changed to “almost always” with re-
gard to how frequently the participant had diarrhea)
in the Weekly Gastrointestinal Diary. No further revi-
sions were made to this questionnaire during wave 2.Time to complete PRO measures
The mean (range) time to complete the PRO mea-
sures during wave 1 of the interviews was 57.4 (38–
111) seconds for the AM Itch Diary, 88 (39–100) sec-
onds for the PM Itch Diary, and 252.8 (167–407) sec-
onds (4.2 [2.8–6.8] minutes) for the PBC-40. The
mean (range) time to complete the PRO measures
during wave 2 of the interviews was 46.5 (28–75) sec-
onds for the AM Itch Diary, 89.8 (47–120) seconds for
the PM Itch Diary, and 291.9 (161–420) seconds (4.9
[2.7–7.0] minutes) for the PBC-40.Table 6 Summary of changes to Itch Diary and PBC-40 as a result o
Measure Total Items in Final Measure Items Left Unchanged
AM Itch Diary 7 4
PM Itch Diary 11 1
PBC-40 43 35
AM, morning; PBC, primary biliary cholangitis; PM, eveningDiscussion
Qualitative interviews of 20 North American participants
with PBC confirmed the overall content of the Itch Diary
and weekly PBC-40 measures in terms of symptoms and
disease impact. Qualitative patient interviews are recog-
nized as being an integral part of developing quality of life
measures and are recommended by the FDA for the
development of PRO measures to support label claims
[15, 16]. Itching-related symptoms were the most com-
monly expressed symptom concept both spontaneously
and overall. Patients reported that itching and fatigue were
the worst of their PBC symptoms. Scratching, sleep issues,
and work limitations associated with PBC appeared to
have the most important impacts on daily life.
While scratching is a behavior that can be directly
observed by others, and is an activity that leaves visible
evidence by way of marks and bleeding, itching is a
symptom and can only be described by the individual
experiencing this sensation. As demonstrated in the
current study and others, PBC-related itching can be
burdensome for patients [6, 7]. However, previously
available tools to assess itch were simplistic measures
of worst itch or were not disease specific, or had limited
evidence to support their content validity [8]. The Itch
Diary was developed to meet the need for a PRO specificallyf cognitive interviews
Items Removed Items Added Items Revised, n, Description
1 1 2
Item wording revised – 1
Response scale revised – 1
1 2 8
Item wording revised – 5
Response scale revised – 7
0 0 8
Item wording revised – 7
Response scale revised – 1
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goal in this study was to confirm the content validity of the
daily Itch Diary, which was the primary endpoint. The Itch
Diary is independent from the PBC-40 questionnaire, and
we wanted to ensure that the diary captured items relevant
to patients with pruritus due to PBC. The findings reported
here suggest that the Itch Diary will be a useful outcome
tool when assessing the efficacy of new treatments for PBC-
related itching.
In addition to the Itch Diary, the current study assessed
an adapted version of the PBC-40 using a recall period of
“past 7 days” instead of “last 4 weeks.” Although the cogni-
tive interviews identified minor issues in the PBC-40, any
major changes needed to be discussed and approved by
the original developers. After consulting with the original
developers, revisions were mainly limited to making minor
grammatical changes, such as changing terms mainly used
in British English to terms more commonly used and
understandable to North Americans.
A limitation of this study is that eligibility was based
on self-reported diagnosis of PBC. However, of the 14
participants with additional medical information provided
by their physician, all 14 had confirmed PBC. Another
limitation is that the patient population was enriched for
patients with moderate to severe PBC-related itch. Thus,
the applicability of the Itch Diary to the generalized PBC
population, or in other conditions, is unknown at this
time.
Conclusion
Qualitative interviews confirmed the relevance and
comprehension of the Itch Diary and the weekly version
of the PBC-40 as fit-for-purpose measures to assess the
relevant symptoms and impacts associated with PBC and
PBC-related itching, and to support the content validity of
the measures. Adaptation of the PBC-40 to a weekly recall
period and for North American English was successful.
These measures will be useful in evaluating the efficacy of
new treatments for PBC-related itch, although further work
is needed to fully evaluate the psychometric properties of
these measures.
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